

For Press

October 28, 2009

Abbott Japan Co., Ltd.  
Eisai Co., Ltd.

**Abbott Submits Marketing Authorization Application of Humira<sup>®</sup> (adalimumab), a Fully Human Monoclonal anti-TNF- $\alpha$  Antibody, for the Treatment of Ankylosing Spondylitis in Japan**

Abbott Japan Co., Ltd. (Pharmaceutical Products Group, Tokyo, President: Glenn S. Warner, "Abbott Japan") and Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito, "Eisai") today

## 1. Glossary

### 1) Ankylosing spondylitis

Ankylosing spondylitis (AS) is a chronic inflammatory disease that manifests first as joint pain and stiffness in the neck, lower back, and hips, as well as hands and feet in some cases, followed by fusion and rigidity of affected joints over time. In rare cases, severe AS with bony ankylosis of the spine and other joints may develop. Typically, AS

treatment of cancer, rheumatoid arthritis, and infections using Morphotek's unique technologies such as Human Morphodoma<sup>®</sup> and Libradoma<sup>™</sup>. In addition, Eisai is investigating immunotherapy for Alzheimer disease in cooperation with BioArctic Neuroscience Inc. in Sweden, and is developing and marketing Humira, a humanized anti-human TNF- $\alpha$  monoclonal antibody, in Japan in cooperation with Abbott Japan. Eisai is thus committed to improving the QOL of patients and their families by producing antibody drugs.

#### **4. About Abbott**

Abbott, headquartered in Chicago, IL, is a global, broad-based health care company devoted to the research and development of new drugs as well as research into, development, manufacturing, marketing, and distribution of pharmaceutical/medical products, nutritional products, medical devices, medical instru